文献速递妇科

117例延胡索酸水合酶缺失型子宫平滑肌瘤的临床病理特征及预后分析

[Clinicopathological features and prognosis of 117 cases of fumarate hydratase-deficient uterine leiomyomas].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2025-01-01

南京医科大学第一附属医院2020年1月至2024年12月诊断的117例延胡索酸水合酶缺失型子宫平滑肌瘤(FH-dUL)患者与130例普通型子宫肌瘤对照比较,FH-dUL患者发病年龄更早、复发率更高(39.3% vs 21.8%,P=0.046),多发性肌瘤和富于细胞性平滑肌瘤为独立复发危险因素。

要点

  • FH-dUL患者中位年龄35岁、首次诊断肌瘤中位年龄29岁,均显著早于普通肌瘤组的41岁和36岁(P均<0.01)。
  • 肌瘤剔除术后FH-dUL组复发率39.3%(22/56)高于普通肌瘤组21.8%(12/55),差异有统计学意义(P=0.046)。
  • 多发性子宫肌瘤(OR=10.709)和富于细胞性子宫平滑肌瘤(OR=9.489)是FH-dUL复发的独立危险因素。

核心结论

  • 临床病理及影像学特征有助于鉴别FH-dUL与普通型子宫肌瘤但缺乏特异性,诊断依据免疫组化检测。
  • FH-dUL肌瘤剔除术后复发率高,多发性子宫肌瘤和富于细胞性子宫平滑肌瘤是独立危险因素。
  • 作者认为对FH-dUL患者术后进行基因检测、遗传咨询、药物治疗预防复发、生育力指导和长期全程管理至关重要。

研究设计与样本

  • 收集2020年1月至2024年12月南京医科大学第一附属医院经手术病理检查及免疫组化检测诊断的117例FH-dUL患者(FH-dUL组)的临床病理及随访资料。
  • 以同期经免疫组化检测证实为非FH-dUL的130例普通型子宫肌瘤患者(普通肌瘤组)作为对照。
  • 比较两组临床病理特征及影像学特征差异,并随访FH-dUL患者复发情况、生育结局及FH基因胚系突变患者肾细胞癌发生情况。

主要发现

  • FH-dUL组中位年龄35岁、首次发现子宫肌瘤中位年龄29岁,均显著早于普通肌瘤组的41岁和36岁(P均<0.01)。
  • FH-dUL组子宫肌瘤剔除术史、多发性肌瘤发生率、肌瘤血流评分、盆腔磁共振弥散加权成像扩散受限比例及常见病理特征发生率均明显高于普通肌瘤组(P均<0.05)。
  • 30例进行基因检测的FH-dUL患者中18例(60.0%)存在FH基因突变,包括9例胚系突变、3例体系突变、6例无法明确变异来源的突变。
  • 9例FH基因胚系突变患者中2例(2/9)发生肾细胞癌。
  • FH-dUL组中位随访时间20个月,肌瘤剔除术后随访满3个月者56例中22例复发,复发率39.3%(22/56);普通肌瘤组中位随访时间18个月,随访满3个月者55例中12例复发,复发率21.8%(12/55);两组比较P=0.046。

临床怎么用

  • 作者认为临床病理特征及影像学特征有助于鉴别FH-dUL与普通型子宫肌瘤,但缺乏特异性,诊断依据免疫组化检测。
  • 作者认为FH-dUL肌瘤剔除术后复发率高,多发性子宫肌瘤和富于细胞性子宫平滑肌瘤是影响复发的独立危险因素。
  • 作者认为对FH-dUL患者术后进行基因检测、遗传咨询、药物治疗预防复发、生育力指导和长期全程管理至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the clinicopathological characteristics and prognosis of fumarate hydratase-deficient uterine leiomyoma (FH-dUL). Methods: Clinical data and follow-up information for 117 patients with FH-dUL diagnosed through surgical pathology and immunohistochemistry in the First Affiliated Hospital of Nanjing Medical University from January 2020 to December 2024, were collected. A control group of 130 patients with common uterine leiomyomas was also included. The differences between the two groups in clinical, imaging, and pathological characteristics were compared. Additionally, recurrence rates, fertility outcomes for FH-dUL patients, and the incidence of renal cancer in FH germline mutation carriers were monitored. Results: (1) Comparison of clinicopathological characteristics: the median age of 117 FH-dUL patients was 35 years, and the median age at first diagnosis of uterine leiomyomas was 29 years, both significantly younger than the control group (41 and 36 years; both P<0.01). The FH-dUL group showed significantly higher incidences of uterine myomectomy, multiple leiomyomas, diffusion restriction on pelvic magnetic resonance imaging diffusion weighted imaging, and typical pathological features (candelabra-like vessels, bizarre nuclei, cytoplasmic eosinophilic globules, perinuclear halo, cellular atypia) and higher ultrasound blood flow score (all P<0.05). Of the 30 FH-dUL patients who underwent genetic testing, 9 had germline mutations, 3 had somatic mutations, and 6 had mutations of unclear origin. Among the 9 FH gene germline mutation patients, 2 had already developed renal cell carcinoma. (2) Recurrence analysis: among the 56 patients who underwent uterine myomectomy, 22 (39.3%, 22/56) experienced recurrence during follow-up, compared to 12 (21.8%, 12/55) of the 55 patients in the control group, the difference between the two groups was statistically significant (P=0.046). Multivariate binary logistic regression analysis showed that cellular leiomyomas (OR=9.489, 95%CI: 1.740-51.755; P=0.009) and multiple uterine leiomyomas (OR=10.709, 95%CI: 1.354-84.683; P=0.025) were significant risk factors for recurrence in FH-dUL. (3) Fertility analysis: among the 66 FH-dUL patients who underwent fertility-preserving surgery, 16 had the intention to have fertility desire, only 2 (2/16) completed their fertility plans during follow-up. Conclusions: Clinicopathological features and imaging features help to differentiate FH-dUL from common type uterine fibroids, but lack specificity, and the diagnosis of FH-dUL is based on immunohistochemistry. The recurrence rate after resection of FH-dUL is high, and cellular and multiple leiomyomas are important predictors of recurrence. It is crucial to perform genetic testing, genetic counseling, drug treatment to prevent recurrence, fertility guidance, and long-term comprehensive management after surgery for FH-dUL management. 目的: 探讨延胡索酸水合酶缺失型子宫平滑肌瘤(FH-dUL)的临床病理特征及预后情况。 方法: 收集2020年1月至2024年12月南京医科大学第一附属医院经手术病理检查及免疫组化检测诊断的117例FH-dUL患者(FH-dUL组)的临床病理资料及随访资料,以同期经免疫组化检测证实为非FH-dUL的130例普通型子宫肌瘤患者(普通肌瘤组)作为对照,比较两组患者的临床病理特征及影像学特征的差异,并随访FH-dUL患者的复发情况、生育结局及FH基因胚系突变患者的肾细胞癌发生情况。 结果: (1)临床病理特征比较:117例FH-dUL组患者的中位年龄、首次发现子宫肌瘤的中位年龄(35、29岁)均显著早于普通肌瘤组(41、36岁;P均<0.01);FH-dUL组患者的子宫肌瘤剔除术史、多发性肌瘤发生率、肌瘤血流评分、盆腔磁共振成像检查弥散加权成像序列扩散受限比例、常见病理特征(包括鹿角状血管、奇异核、胞质嗜酸小球、核周透明晕、细胞异型性)的发生率均明显高于普通肌瘤组(P均<0.05)。30例进行基因检测的FH-dUL患者中,18例(60.0%)存在FH基因突变,包括9例胚系突变、3例体系突变、6例无法明确变异来源的突变。9例FH基因胚系突变患者中,2例(2/9)患者发生肾细胞癌。(2)复发情况及影响因素分析:FH-dUL组患者的中位随访时间为20个月,肌瘤剔除术后随访时间满3个月者56例,其中22例复发,复发率为39.3%(22/56);普通肌瘤组患者的中位随访时间为18个月,肌瘤剔除术后随访时间满3个月者55例,其中12例复发,复发率为21.8%(12/55);两组复发率比较,差异有统计学意义(P=0.046)。多因素二元logistic回归分析显示,多发性子宫肌瘤(OR=10.709,95%CI为1.354~84.683;P=0.025)、富于细胞性子宫平滑肌瘤(OR=9.489,95%CI为1.740~51.755;P=0.009)均是影响FH-dUL患者肌瘤剔除术后复发的独立危险因素。(3)生育结局:66例行肌瘤剔除术的FH-dUL患者中,16例有生育意愿,随访期间仅有2例(2/16)完成了生育计划。 结论: 临床病理特征及影像学特征有助于鉴别FH-dUL与普通型子宫肌瘤,但缺乏特异性,FH-dUL的诊断依据免疫组化检测。FH-dUL肌瘤剔除术后复发率高,多发性子宫肌瘤和富于细胞性子宫平滑肌瘤是影响FH-dUL复发的独立危险因素。对FH-dUL患者术后进行基因检测、遗传咨询、药物治疗预防复发、生育力指导和长期全程管理至关重要。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yu WN, Pan SY, Wang C, et al. [Clinicopathological features and prognosis of 117 cases of fumarate hydratase-deficient uterine leiomyomas]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 40582968. doi:10.3760/cma.j.cn112141-20250205-00040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。